Vivek Subbiah, Director of Rare Cancer Program at NYU Langone Health, shared on LinkedIn:
“New city, new chapter, same mission
I’m delighted to share that I’ve joined NYU Langone Health Perlmutter Cancer Center as Director of the Early Phase Drug Development Program and Director of the Rare Cancer Program and will be Professor of Medicine at NYU Grossman School of Medicine.
What drew me to Perlmutter Cancer Center NYU Langone Health New York University is how quickly this team moves to bring new treatments to patients. Cancer is deeply personal and patients can’t wait.
My goal is to get promising therapies to them as quickly and safely as possible.
For patients with rare cancers, Precision Medicine should open the door to treatment. Expanding access to early-phase trials is how we make that real.
My work has always been tumor agnostic and will continue geography agnostic and zip code agnostic too.
I’m deeply grateful to Anirban Maitra, John Leonard and the NYU Langone leadership for bringing me here.
Thank you to my colleagues at Stanford University, Sarah Cannon Research Institute and UT MD ANDERSON CANCER CENTER who shaped so much of this journey. And thank you to all my friends and colleagues for the wishes and the outpouring of support.
Such a delight to be in New York with family.
Let’s get to work”
You may also be interested in:
Anirban Maitra: What’s Coming Next From NYU Langone Health?
Vivek Subbiah: Joining the International Alliance for Personalised Medicine Event at ESMO 2026
Anirban Maitra Welcomes Ishwaria Mohan Subbiah to Perlmutter Cancer Center at NYU Langone Health